Pivotal trial results for risankizumab (Skyrizi) as maintenance therapy for moderately to severely active Crohn's disease were published on January 1, 2022. The study, known as FORTIFY, investigated the efficacy and safety of the drug in this patient population.
Background
The published results concern risankizumab (Skyrizi), an investigational maintenance therapy for moderately to severely active Crohn's disease. Crohn's disease is a chronic inflammatory bowel disease that can affect any part of the gastrointestinal tract, leading to symptoms such as abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Effective maintenance therapies are crucial for managing the long-term progression of the disease and improving patients' quality of life.
Trial design
The FORTIFY study was a multicentre, randomised, double-blind, placebo-controlled trial. It investigated the efficacy and safety of risankizumab as a maintenance therapy in participants with moderately to severely active Crohn's disease.
What this means
The publication of these pivotal trial results for risankizumab in moderately to severely active Crohn's disease provides important data for clinicians and researchers. While specific efficacy and safety outcomes are not detailed in the provided information, the release of these findings allows for a comprehensive evaluation of risankizumab as a potential maintenance therapy for this chronic condition. These results contribute to the growing body of evidence for therapeutic options in Crohn's disease management.
Source
The information regarding the publication of these trial results was obtained from PubMed. The article, titled 'Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlle', was published on 2022-01-01, and is accessible via pubmed.ncbi.nlm.nih.gov.